» Articles » PMID: 36467425

Gut-kidney Axis in IgA Nephropathy: Role on Mesangial Cell Metabolism and Inflammation

Overview
Specialty Cell Biology
Date 2022 Dec 5
PMID 36467425
Authors
Affiliations
Soon will be listed here.
Abstract

IgA Nephropathy (IgAN) is the commonest primary glomerular disease around the world and represents a significant cause of end-stage renal disease. IgAN is characterized by mesangial deposition of IgA-immune complexes and mesangial expansion. The pathophysiological process includes an abnormally glycosylated IgA1, which is an antigenic target. Autoantibodies specifically recognize galactose-deficient IgA1 forming immune complexes that are amplified in size by the soluble IgA Fc receptor CD89 leading to deposition in the mesangium through interaction with non-classical IgA receptors. The local production of cytokines promotes local inflammation and complement system activation, besides the stimulation of mesangial proliferation. The spectrum of clinical manifestations is quite variable from asymptomatic microscopic hematuria to rapidly progressive glomerulonephritis. Despite all the advances, the pathophysiology of the disease is still not fully elucidated. The mucosal immune system is quoted to be a factor in triggering IgAN and a "gut-kidney axis" is proposed in its development. Furthermore, many recent studies have demonstrated that food intake interferes directly with disease prognosis. In this review, we will discuss how mucosal immunity, microbiota, and nutritional status could be interfering directly with the activation of intrinsic pathways of the mesangial cells, directly resulting in changes in their function, inflammation and development of IgAN.

Citing Articles

Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.

Yao K, Zheng L, Chen W, Xie Y, Liao C, Zhou T Front Immunol. 2025; 16:1438683.

PMID: 39981255 PMC: 11839611. DOI: 10.3389/fimmu.2025.1438683.


Immunoglobulin A Antibodies: From Protection to Harmful Roles.

Gleeson P, Camara N, Launay P, Lehuen A, Monteiro R Immunol Rev. 2024; 328(1):171-191.

PMID: 39578936 PMC: 11659943. DOI: 10.1111/imr.13424.


Drugs in Development to Treat IgA Nephropathy.

Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F Drugs. 2024; 84(5):503-525.

PMID: 38777962 DOI: 10.1007/s40265-024-02036-1.


Hirudin in the Treatment of Chronic Kidney Disease.

Liu S, Cao Y, Zhang C Molecules. 2024; 29(5).

PMID: 38474541 PMC: 10935440. DOI: 10.3390/molecules29051029.


Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022.

Chen X, Yan Z, Pan Q, Zhang C, Chen Y, Liang X Immun Inflamm Dis. 2024; 12(1):e1156.

PMID: 38270317 PMC: 10807354. DOI: 10.1002/iid3.1156.


References
1.
Hu X, Du J, Xie Y, Huang Q, Xiao Y, Chen J . Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study. BMC Nephrol. 2020; 21(1):97. PMC: 7071635. DOI: 10.1186/s12882-020-01741-9. View

2.
Nagy J, Scott H, Brandtzaeg P . Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol. 1988; 29(6):275-9. View

3.
Schmitt R, Stahl A, Olin A, Kristoffersson A, Rebetz J, Novak J . The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol. 2014; 193(1):317-26. PMC: 4065838. DOI: 10.4049/jimmunol.1302249. View

4.
Wu G, Peng Y, Liu H, Hou Q, Liu F, Chen N . Expression of CD19(+)CD5(+)B cells and IgA1-positive cells in tonsillar tissues of IgA nephropathy patients. Ren Fail. 2011; 33(2):159-63. DOI: 10.3109/0886022X.2011.552150. View

5.
Tjon J, van Bergen J, Koning F . Celiac disease: how complicated can it get?. Immunogenetics. 2010; 62(10):641-51. PMC: 2944025. DOI: 10.1007/s00251-010-0465-9. View